TY - JOUR
T1 - Perceived physical health outcomes of direct-acting antiviral treatment for hepatitis C
T2 - a qualitative study
AU - Goutzamanis, Stelliana
AU - Horyniak, Danielle
AU - Doyle, Joseph S.
AU - Hellard, Margaret
AU - Higgs, Peter
AU - on behalf of the Treatment and Prevention Study group
N1 - Funding Information:
The author(s) received no financial support for the research, authorship, and/or publication of this article except DH who was supported by National Health and Medical Research Council Grant No. 1092077.
Publisher Copyright:
© 2021, The Author(s).
Copyright:
Copyright 2021 Elsevier B.V., All rights reserved.
PY - 2021/7/15
Y1 - 2021/7/15
N2 - Background: Novel health promotion and treatment uptake initiatives will be necessary to ensure Australia meets 2030 hepatitis C elimination targets. Increasing treatment uptake will be assisted by a better understanding of the treatment experience and patient-perceived benefits. This study describes the perceived physical health benefits from direct-acting antiviral (DAA) hepatitis C treatment among people who inject drugs in Melbourne, Australia. Methods: Twenty participants were recruited from a community treatment trial and community health clinics. Semi-structured interviews were performed with each participant before, during and following treatment. Interviews focused on treatment experiences, attitudes and motivations. Interviews were recorded, transcribed and thematically analysed. Results: Two themes relating to the physical experience of treatment developed; intersection between physical and mental health and “maybe it’s working”. Participants reported various physical benefits, most prominently, reduced fatigue. Reductions in fatigue resulted in instant and meaningful changes in everyday life. Some participants did experience side effects, which they described as mild. Experiencing noticeable physical benefits during treatment was perceived as validation that treatment was working. Conclusion: Physical health benefits of DAA treatment may have carry-on effects on cognitive, emotional or social wellbeing and should be incorporated into how treatment is promoted to those who require it.
AB - Background: Novel health promotion and treatment uptake initiatives will be necessary to ensure Australia meets 2030 hepatitis C elimination targets. Increasing treatment uptake will be assisted by a better understanding of the treatment experience and patient-perceived benefits. This study describes the perceived physical health benefits from direct-acting antiviral (DAA) hepatitis C treatment among people who inject drugs in Melbourne, Australia. Methods: Twenty participants were recruited from a community treatment trial and community health clinics. Semi-structured interviews were performed with each participant before, during and following treatment. Interviews focused on treatment experiences, attitudes and motivations. Interviews were recorded, transcribed and thematically analysed. Results: Two themes relating to the physical experience of treatment developed; intersection between physical and mental health and “maybe it’s working”. Participants reported various physical benefits, most prominently, reduced fatigue. Reductions in fatigue resulted in instant and meaningful changes in everyday life. Some participants did experience side effects, which they described as mild. Experiencing noticeable physical benefits during treatment was perceived as validation that treatment was working. Conclusion: Physical health benefits of DAA treatment may have carry-on effects on cognitive, emotional or social wellbeing and should be incorporated into how treatment is promoted to those who require it.
KW - Direct-acting antiviral
KW - Hepatitis C
KW - People who inject drugs
KW - Qualitative research
KW - Quality of life
KW - Treatment experience
UR - https://www.scopus.com/pages/publications/85110095112
U2 - 10.1186/s12954-021-00516-1
DO - 10.1186/s12954-021-00516-1
M3 - Article
C2 - 34266434
AN - SCOPUS:85110095112
SN - 1477-7517
VL - 18
JO - Harm Reduction Journal
JF - Harm Reduction Journal
IS - 1
M1 - 73
ER -